SCM
IONS icon

Soleus Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Soleus Capital Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-19,648
Closed -$932K – 72
2020
Q3 		$932K Sell
19,648
-16,752
-46% -$931K 0.49% 45
2020
Q2 		$2.15M Buy
+36,400
New +$2.02M 1.22% 28

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Soleus Capital Management's IONS Position: Q4 2020 in Review

Soleus Capital Management sold out of Ionis Pharmaceuticals (IONS) in Q4 2020, closing a stake of 19,648 shares — an estimated $932K sold.

Soleus Capital Management first reported a position in IONS in Q2 2020 and held it in 2 quarters. The position peaked at $2.15M in Q2 2020. 382 funds tracked by Wall St. Rank hold IONS as of Q4 2020.

  • Soleus Capital Management reported no remaining Ionis Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Soleus Capital Management sold 19,648 Ionis Pharmaceuticals shares in Q4 2020, an estimated $932K.
  • Soleus Capital Management first reported a position in Ionis Pharmaceuticals in Q2 2020 and held it in 2 quarters.
  • Soleus Capital Management's Ionis Pharmaceuticals position peaked at $2.15M in Q2 2020.
  • 382 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2020.

Based on Soleus Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.